Skip to main content

Table 1 Baseline characteristics in training and validation cohorts

From: Development, validation, and visualization of a web-based nomogram to predict 5-year mortality risk in older adults with hypertension

Variables training cohort validation cohort
  (n = 2691) (n = 1737)
Demographic
 Age, years 74.70 ± 6.41 73.74 ± 5.17
Sex, n (%)
 Male 1311 (48.7) 848 (48.8)
 Female 1380 (51.3) 889 (51.2)
Ethnicity, n (%)
 Non-Hispanic White 1675 (62.2) 1090 (62.8)
 Non-Hispanic Black 453 (16.8) 286 (16.5)
 Other Hispanic 75 (2.8) 119 (6.9)
 Other races 488 (18.1) 242 (13.9)
Education, n (%)
 less than high-school 1111 (41.3) 631 (36.3)
 high school or above 1580 (58.7) 1106 (63.7)
Marital status, n (%)
 Married 1477 (54.9) 958 (55.2)
 Widowed or divorced 1099 (40.8) 694 (40.0)
 Single 115 (4.3) 85 (4.9)
The income to poverty ratios, n (%)
 ≤1.3 1885 (70.0) 1237 (71.2)
 > 1.3 806 (30.0) 500 (28.8)
Smoking, n (%)
 Never 1312 (48.8) 817 (47.0)
 Former 1152 (42.8) 759 (43.7)
 Current 227 (8.4) 161 (9.3)
Comorbidities
Cardiovascular disease, n (%)
 Absence 1890 (70.2) 1216 (70.0)
 Presence 801 (29.8) 521 (30.0)
Diabetes, n (%)
 Absence 1979 (73.5) 1175 (67.6)
 Presence 712 (26.5) 562 (32.4)
Biomeasures
Body mass index, kg/m2, n (%)
 < 25 735 (27.3) 435 (25.0)
 25-30 1084 (40.3) 652 (37.5)
 ≥30 872 (32.4) 650 (37.4)
 Systolic blood pressure, mmHg 148.97 ± 22.69 142.07 ± 21.56
 Diastolic blood pressure, mmHg 69.90 ± 13.73 67.07 ± 13.34
 Total cholesterol /High density lipoprotein cholesterol 4.07 ± 1.32 3.85 ± 1.32
 White blood cells, 1000 cells/uL 7.14 ± 2.88 7.07 ± 2.21
 Hemoglobin, g/dL 14.06 ± 1.45 13.81 ± 1.53
 Platelet, 1000 cells/uL 251.01 ± 70.90 237.57 ± 69.72
 Albumin, g/dL 41.91 ± 3.03 41.55 ± 3.02
 Blood urea nitrogen, mg/dL 6.28 ± 2.84 6.33 ± 2.90
 eGFR, mg/min/1.73 m2 69.94 ± 20.92 68.53 ± 19.52
 HbA1C, % 5.92 ± 1.02 6.06 ± 0.93
Drugs
Antihypertensive drugs, n (%)
 Absence 963 (35.8) 421 (24.2)
 Presence 1728 (64.2) 1316 (75.8)
Hypoglycemic agents, n (%)
 Absence 2288 (85.0) 1483 (85.4)
 Presence 403 (15.0) 254 (14.6)
Lipid-lowering drugs, n (%)
 Absence 1898 (70.5) 1016 (58.5)
 Presence 793 (29.5) 721 (41.5)
Antiplatelet drugs, n (%)
 Absence 2550 (94.8) 1515 (87.2)
 Presence 141 (5.2) 222 (12.8)
5-year mortality, n (%)
 Survival 2174 (80.8) 1440 (82.9)
 Death 517 (19.2) 297 (17.1)
  1. HbA1C hemoglobin, eGFR estimated glomerular filtration rate